Skip Navigation
Skip to contents

Journal of Microbiology : Journal of Microbiology

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
1 "squirrelpox virus"
Filter
Filter
Article category
Keywords
Publication year
Review
Replicating poxviruses for human cancer therapy
Manbok Kim
J. Microbiol. 2015;53(4):209-218.   Published online April 8, 2015
DOI: https://doi.org/10.1007/s12275-015-5041-4
  • 60 View
  • 0 Download
  • 24 Crossref
AbstractAbstract
Naturally occurring oncolytic viruses are live, replicationproficient viruses that specifically infect human cancer cells while sparing normal cell counterparts. Since the eradication of smallpox in the 1970s with the aid of vaccinia viruses, the vaccinia viruses and other genera of poxviruses have shown various degrees of safety and efficacy in pre-clinical or clinical application for human anti-cancer therapeutics. Furthermore, we have recently discovered that cellular tumor suppressor genes are important in determining poxviral oncolytic tropism. Since carcinogenesis is a multi-step process involving accumulation of both oncogene and tumor suppressor gene abnormalities, it is interesting that poxvirus can exploit abnormal cellular tumor suppressor signaling for its oncolytic specificity and efficacy. Many tumor suppressor genes such as p53, ATM, and RB are known to play important roles in genomic fidelity/maintenance. Thus, tumor suppressor gene abnormality could affect host genomic integrity and likely disrupt intact antiviral networks due to accumulation of genetic defects, which would in turn result in oncolytic virus susceptibility. This review outlines the characteristics of oncolytic poxvirus strains, including vaccinia, myxoma, and squirrelpox virus, recent progress in elucidating the molecular connection between oncogene/tumor suppressor gene abnormalities and poxviral oncolytic tropism, and the associated preclinical/clinical implications. I would also like to propose future directions in the utility of poxviruses for oncolytic virotherapy.

Citations

Citations to this article as recorded by  
  • Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy
    Shashi Gujar, Jonathan G. Pol, Vishnupriyan Kumar, Manuela Lizarralde-Guerrero, Prathyusha Konda, Guido Kroemer, John C. Bell
    Nature Protocols.2024; 19(9): 2540.     CrossRef
  • A Comparative Study of Oncolytic Vaccinia Viruses Harboring Different Marine Lectins in Breast Cancer Cells
    Yanrong Zhou, Qianpeng Wang, Qi Ying, Xiaomei Zhang, Ting Ye, Kan Chen, Gongchu Li
    Marine Drugs.2023; 21(2): 77.     CrossRef
  • Poxvirus-driven human diseases and emerging therapeutics
    Kritika Srinivasan Rajsri, Mana Rao
    Therapeutic Advances in Infectious Disease.2022;[Epub]     CrossRef
  • The O H system: A panorama view of the PPV-host interaction
    Yongzhong Yu, Zhengxing Lian, Yudong Cui
    Infection, Genetics and Evolution.2022; 98: 105220.     CrossRef
  • Anti-Tumor Effects of MAPK-Dependent Tumor-Selective Oncolytic Vaccinia Virus Armed with CD/UPRT against Pancreatic Ductal Adenocarcinoma in Mice
    Hajime Kurosaki, Motomu Nakatake, Teruhisa Sakamoto, Nozomi Kuwano, Masato Yamane, Kenta Ishii, Yoshiyuki Fujiwara, Takafumi Nakamura
    Cells.2021; 10(5): 985.     CrossRef
  • Oncolytic Vaccinia Virus Expressing White-Spotted Charr Lectin Regulates Antiviral Response in Tumor Cells and Inhibits Tumor Growth In Vitro and In Vivo
    Xue Wang, Ningning Zhou, Tingting Liu, Xiaoyuan Jia, Ting Ye, Kan Chen, Gongchu Li
    Marine Drugs.2021; 19(6): 292.     CrossRef
  • Novel Oncolytic Virus Armed with Cancer Suicide Gene and Normal Vasculogenic Gene for Improved Anti-Tumor Activity
    Su-Nam Jeong, So Young Yoo
    Cancers.2020; 12(5): 1070.     CrossRef
  • Oncolytic Virotherapy for Malignant Tumor: Current Clinical Status
    Yuhui Zhang, Zhuoming Liu
    Current Pharmaceutical Design.2020; 25(40): 4251.     CrossRef
  • Viral and metazoan poxins are cGAMP-specific nucleases that restrict cGAS–STING signalling
    James B. Eaglesham, Youdong Pan, Thomas S. Kupper, Philip J. Kranzusch
    Nature.2019; 566(7743): 259.     CrossRef
  • Targeted therapy of human glioblastoma combining the oncolytic properties of parvovirus H-1 and attenuated strains of the vaccinia virus
    A. V. Tkacheva, G. F. Sivolobova, A. A. Grazhdantseva, O. B. Shevelev, I. A. Razumov, E. L. Zavjalov, V. B. Loktev, G. V. Kochneva
    Molecular Genetics Microbiology and Virology (Russian version).2019; 37(2): 83.     CrossRef
  • Poxvirus oncolytic virotherapy
    Lino E. Torres-Domínguez, Grant McFadden
    Expert Opinion on Biological Therapy.2019; 19(6): 561.     CrossRef
  • Targeted Therapy of Human Glioblastoma Combining the Oncolytic Properties of Parvovirus H-1 and Attenuated Strains of the Vaccinia Virus
    A. V. Tkacheva, G. F. Sivolobova, A. A. Grazhdantseva, O. B. Shevelev, I. A. Razumov, E. L. Zavjalov, V. B. Loktev, G. V. Kochneva
    Molecular Genetics, Microbiology and Virology.2019; 34(2): 140.     CrossRef
  • Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines
    Edmund K. Moon, Liang-Chuan S. Wang, Kheng Bekdache, Rachel C. Lynn, Albert Lo, Stephen H. Thorne, Steven M. Albelda
    OncoImmunology.2018; 7(3): e1395997.     CrossRef
  • Development of improved therapeutic mesothelin-based vaccines for pancreatic cancer
    Michael White, Andrew Freistaedter, Gwendolyn J. B. Jones, Emmanuel Zervos, Rachel L. Roper, Aamir Ahmad
    PLOS ONE.2018; 13(2): e0193131.     CrossRef
  • Mutagenic repair of double-stranded DNA breaks in vaccinia virus genomes requires cellular DNA ligase IV activity in the cytosol
    Rutger David Luteijn, Ingo Drexler, Geoffrey L. Smith, Robert Jan Lebbink, Emmanuel J. H. J. Wiertz
    Journal of General Virology.2018; 99(6): 790.     CrossRef
  • Oncolytic viruses: emerging options for the treatment of breast cancer
    Yogesh R. Suryawanshi, Tiantian Zhang, Karim Essani
    Medical Oncology.2017;[Epub]     CrossRef
  • Primary lymphocyte infection models for KSHV and its putative tumorigenesis mechanisms in B cell lymphomas
    Sangmin Kang, Jinjong Myoung
    Journal of Microbiology.2017; 55(5): 319.     CrossRef
  • Oncolytic virus efficiency inhibited growth of tumour cells with multiple drug resistant phenotype in vivo and in vitro
    Elena P. Goncharova, Julia S. Ruzhenkova, Ivan S. Petrov, Sergey N. Shchelkunov, Marina A. Zenkova
    Journal of Translational Medicine.2016;[Epub]     CrossRef
  • Oncolytic virotherapy for urological cancers
    Zahid Delwar, Kaixin Zhang, Paul S. Rennie, William Jia
    Nature Reviews Urology.2016; 13(6): 334.     CrossRef
  • Features of the Antitumor Effect of Vaccinia Virus Lister Strain
    Evgeniy Zonov, Galina Kochneva, Anastasiya Yunusova, Antonina Grazhdantseva, Vladimir Richter, Elena Ryabchikova
    Viruses.2016; 8(1): 20.     CrossRef
  • Single-particle characterization of oncolytic vaccinia virus by flow virometry
    Vera A. Tang, Tyler M. Renner, Oliver Varette, Fabrice Le Boeuf, Jiahu Wang, Jean-Simon Diallo, John C. Bell, Marc-André Langlois
    Vaccine.2016; 34(42): 5082.     CrossRef
  • Use of Reporter Genes in the Generation of Vaccinia Virus-Derived Vectors
    Sally Al Ali, Sara Baldanta, Mercedes Fernández-Escobar, Susana Guerra
    Viruses.2016; 8(5): 134.     CrossRef
  • Naturally occurring reoviruses for human cancer therapy
    Manbok Kim
    BMB Reports.2015; 48(8): 454.     CrossRef
  • Reoviral Oncotropism Against c-Myc Overexpressing HS 68 Cells
    Manbok Kim
    Journal of Bacteriology and Virology.2015; 45(2): 126.     CrossRef

Journal of Microbiology : Journal of Microbiology
TOP